Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: Clinical outcome
Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: Clinical outcome
复制标题
DOI：
10.1016/j.radonc.2009.02.011
复制
发表时间：
2009-06-01
影响因子：
5.7
通讯作者：
Nuyttens, Joost J.
中科院分区：
文献类型：
--
作者：
van Zyp, Noelle C. van der Voort;Prevost, Jean-Briac;Nuyttens, Joost J.
目的：报道70例不能手术治疗的I期非小细胞肺癌（NSCLC）患者的实时肿瘤追踪治疗结果。材料与方法：70例不能手术治疗的周围型早期NSCLC患者，采用射波刀分3次给予45或60戈伊治疗。51%的患者可获得病理学检查结果。39名患者患有T1肿瘤，31名患者患有T2肿瘤。标记放置使用血管，经皮肺内，或肺外的方法，根据气胸的风险。结果：精算2年的局部控制率为60戈伊治疗的患者为96%，而78%的患者治疗总剂量为45戈伊（p = 0.197）。所有局部复发（n = 4）发生在T2肿瘤患者。全组2年总生存率为62%，病因特异性生存率为85%。中位随访时间为15个月。2例患者（3%）在标记物放置后发生3级毒性。7例患者（10%）发生治疗相关晚期3级毒性。结论：采用实时肿瘤追踪技术，分三次给予60戈伊的剂量，对NSCLC患者进行治疗，术后1年和2年的局部控制率均达到96%。毒性低。(C)2009爱思唯尔爱尔兰有限公司保留所有权利。放射治疗和肿瘤学91（2009）296-300
Purpose: To report the clinical outcome of treatment using real-time tumor tracking for 70 patients with inoperable stage I non-small cell lung cancer (NSCLC).Materials and methods: Seventy inoperable patients with peripherally located early-stage NSCLC were treated with 45 or 60 Gy in three fractions using CyberKnife. Pathology was available in 51% of patients. Thirty-nine patients had a T1-tumor and 31 had a T2-tumor. Markers were placed using the vascular, percutaneous intra-, or extra-pulmonary approach, depending on the risk of pneumothorax.Results: The actuarial 2-year local control rate for patients treated with 60 Gy was 96%, compared to 78% for patients treated with a total dose of 45 Gy (p = 0.197). All local recurrences (n = 4) occurred in patients with T2-tumors. Overall survival for the whole group at two years was 62% and the cause specific survival was 85%. The median follow-up was 15 months. Grade 3 toxicity occurred in two patients (3%) after marker placement. Treatment-related late grade 3 toxicity occurred in 7 patients (10%). No grade >= 4 toxicity occurred.Conclusion: Excellent local control of 96% at 1- and 2-years was achieved using 60 Gy in three fractions for NSCLC patients treated with the real-time tumor tracking. Toxicity was low. (C) 2009 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 91 (2009) 296-300